MNOV Medicinova Inc

2

Amendment No. 2 to Schedule 13D

This Amendment No. 2 (the “Amendment”) amends and supplements the Schedule 13D filed on October 19, 2011, as amended by Amendment No. 1 to Schedule 13D filed on May 17, 2016 (the “Statement”) by Kissei Pharmaceutical Co., Ltd. (“Kissei”), relating to the common stock (the “Common Stock”), par value $0.001 per share, of MediciNova, Inc., a Delaware corporation (the “Company”). Information reported in the Statement remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment. Capitalized terms used but not defined in this Amendment have the respective meanings set forth in the Statement.

Kissei’s beneficial ownership has dropped below the 5% Schedule 13D reporting threshold. Therefore, this Amendment constitutes the final amendment to Kissei’s Statement and terminates the Kissei’s obligation to further amend the Statement.

Items 1, 2, 3, 4 and 5 of the Statement are hereby amended and supplements as follows:

Item 1. Security and Issuer

This Statement relates to the Common Stock of MediciNova, Inc., a Delaware Corporation. The principal executive offices of the Company are located at 4275 Executive Square, Suite 650, La Jolla, CA 92037.

Item 2. Identity and Background

Item 2 is hereby amended and restated to read in its entirety as follows:

This Statement is being filed by KISSEI PHARMACEUTICAL CO., LTD. Kissei is a joint stock corporation organized under the laws of Japan. The address of the principal business and principal office of Kissei is 19-48, Yoshino, Matsumoto-City, Nagano-Prefecture 399-8710, Japan.

Kissei’s principal business is the research, development and marketing of pharmaceutical products. Kissei was founded in 1946 and has grown into one of Japan’s leading pharmaceutical companies. Kissei’s management vision is to be a research and development-oriented pharmaceutical company that contributes to the health of people around the world through developing and offering innovative drugs.

The name, business address, present principal occupation or employment and citizenship of each director and executive officer (including a director and officer who may be a controlling person) of Kissei is set forth on Schedule A attached hereto. During the last five years, none of Kissei nor, to the knowledge of Kissei, any of the persons listed on Schedule A, has been convicted in a criminal proceeding (excluding traffic violations or

3

similar misdemeanors) or has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 is hereby amended by adding the following thereto:

On June 13, 2017, Kissei sold an aggregate of 800,000 shares of the Company’s Common Stock, at a price of JPY602 per share, for an aggregate sale price of JPY481,600,000. The transactions were effectuated after hours on the Tokyo Stock Exchange. No funds were used in making the transactions giving rise to this Amendment.

Item 4. Purpose of Transaction

The information set forth in Item 3 of the Statement and this Amendment is hereby incorporated by reference in its entirety into this Item 4.

Item 4 is hereby amended by adding the following thereto:

The shares held by Kissei are held for investment purposes. Kissei intends to continuously review their investment in the Company, and may in the future determine, subject to any legal and contractual restrictions, (i) to acquire additional securities of the Company, through open market purchases, private agreements or otherwise, (ii) to dispose of all or a portion of the securities of the Company owned by them or (iii) to take any other available course of action, which could involve one or more of the types of transactions or have one or more of the results, as specified in clauses (a) through (j) of Item 4 of Schedule 13D. Notwithstanding anything contained herein, Kissei specifically reserves the right to change their intention with respect to any or all of such matters. In reaching any decision as to its course of action (as well as to the specific elements thereof), Kissei currently expects that they would take into consideration a variety of factors, including, but not limited to, the following: the Company’s business and prospects; other developments concerning the Company and its business generally; other business opportunities available to Kissei; developments with respect to the business of Kissei; changes in law and government regulations; general economic conditions and the conditions in the industries served by Kissei and the Company, respectively; and money and stock market conditions, including the market price of the securities of the Company; and Kissei’s contractual obligations with respect to the shares.

The name, business address, present principal occupation or employment and citizenship of each director and executive officer (including a director and officer who may be a controlling person) of Kissei is set forth on Schedule A attached hereto

4

Item 5. Interest in Securities of the Issuer

Item 5 is hereby amended and restated to read in its entirety as follows:

(a) and (b)

For purposes of calculating the percentages set forth in this Item 5, the number of shares of Common Stock outstanding was assumed to be 34,540,453 shares outstanding on April 13, 2017 as reported by the Company in its Definitive Proxy Statement on Schedule 14A.

As of June 13, 2017, Kissei beneficially owns 1,400,000 shares of the Company’s Common Stock, representing approximately 4.1% of the Company’s outstanding Common Stock. For purposes of this calculation, Kissei has assumed no exercise or conversion of any other outstanding securities that may be exercisable for or convertible into Common Stock.

Kissei has sole voting and dispositive power with respect to the Common Stock.

(c)

Except for the transactions described above, to the knowledge of Kissei, no transactions in the class of securities reported have been effected during the past 60 days by Kissei or any person named in Schedule A.

(d)

To the knowledge of Kissei, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities of the Company reported herein.

(e)

Kissei ceased to beneficially own, or be deemed to beneficially own, more than 5% of the Company’s Common Stock on June 13, 2017.

5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

SCHEDULE A

Directors and Executive Officers of Kissei

The name, current principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted, of each of the executive officers and directors of KISSEI PHARMACEUTICAL CO. LTD. (“Kissei”) are set forth below. Unless otherwise indicated, the business address of each director and officer is care of KISSEI PHARMACEUTICAL CO. LTD., 19-48, Yoshino, Matsumoto-City, Nagano-Prefecture 399-8710, Japan. Unless otherwise indicated, each occupation set forth under an individual’s name refers to employment with Kissei. All directors and officers listed below are citizens of Japan.